SEC Form 4 · accession 0001179110-16-018828
Editas Medicine, Inc. · EDIT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Katrine Bosley
Officer — President and CEO · Director
Period of report
Feb 8, 2016
Accepted (ET)
Feb 9, 2016 · 5:41 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001650664
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 8, 2016 | C | 73,856 | — | A | 1,436,822 | D | |
| Common StockF1 | Feb 8, 2016 | C | 4,273 | — | A | 1,441,095 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A-2 Preferred StockF1 | — | Feb 8, 2016 | C | 192,027 | D | — | — | Common Stock | 73,856 | 0 | D |
| Series B Preferred StockF1 | — | Feb 8, 2016 | C | 11,111 | D | — | — | Common Stock | 4,273 | 0 | D |
Explanation of responses
- F1The Series A-2 and Series B Preferred Stock converted into Common Stock on a 2.6-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 and B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.